CHICAGO--(BUSINESS WIRE)--Allegro Ophthalmics, LLC, dedicated to establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of vitreo-retinal diseases, today announced that it is enrolling patients in a Phase 2 trial that will evaluate the safety and efficacy of Luminate®, previously known as ALG-1001, in patients with diabetic macular edema (DME).
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
